Related Experiment Video
Updated: Oct 8, 2025
06:34
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
Published on: November 29, 2024
401
Naturally Occurring SGLT2 Inhibitors: A Review
Habib Yaribeygi1, Milad Ashrafizadeh2,3, Thozhukat Sathyapalan4
1Research Center of Physiology, Semnan University of Medical Sciences, Semnan, Iran. habib.yari@yahoo.com.
Advances in Experimental Medicine and Biology
|January 4, 2022
Summary
Discover natural compounds that mimic SGLT2 inhibitors for diabetes management. This review explores phytochemicals that reduce blood glucose by inhibiting sodium-glucose cotransporter activity, offering a potential alternative to synthetic drugs.
Area of Science:
- Endocrinology
- Pharmacology
- Natural Product Chemistry
Background:
- Global rise in diabetes mellitus necessitates novel therapeutic strategies.
- Current antidiabetic drugs often have undesirable side effects.
- Plant-derived compounds show promise for diabetes management.
Purpose of the Study:
- To review phytochemicals with Sodium-glucose cotransporter inhibitor (SGLT2) like activity.
- To explore natural agents as potential alternatives for diabetes treatment.
Main Methods:
- Literature review of studies on phytochemicals and SGLT2 inhibition.
- Analysis of mechanisms by which natural compounds affect glucose metabolism.
Main Results:
- Certain nutraceutical agents exhibit SGLT2 inhibitory effects.
- Phytochemicals can reduce blood glucose levels through mechanisms similar to SGLT2 inhibitors.
Conclusions:
- Plant-derived compounds offer a potential avenue for developing new antidiabetic treatments.
- Further research into phytochemicals acting as SGLT2 inhibitors is warranted.
Related Concept Videos
01:27Glucose Transporters
25.7K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
25.7K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
307
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
307
01:24Glucagon-like Receptor Agonists
462
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
462
01:23Dipeptidyl Peptidase 4 Inhibitors
280
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
280
01:06Oral Hypoglycemic Agents: Glinides
291
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
291
01:17Oral Hypoglycemic Agents: Sulfonylureas
382
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
382